Primary mediastinal B-cell lymphoma (PMBL) is an entity of B-cell lymphoma distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We investigated the prevalence, specificity and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin-β nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray-zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT-185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP-defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild-type cases. KPT-185 induced a dose-dependent decrease in cell proliferation and increased celldeath in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT-330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein.
Introduction
Although diffuse large B-cell lymphoma (DLBCL) patients have greatly benefited from immunochemotherapy combinations in the past decade, between 30% and 40% of patients currently do not respond to treatment and rapidly relapse, emphasizing the need to understand the mechanisms involved and to identify predictive biomarkers. Primary mediastinal B-cell lymphoma (PMBL) is an entity of aggressive B-cell lymphoma that is clinically and biologically distinct from the other molecular subtypes of DLBCL, such as the germinal center B-cell-like (GCB) and activated B-celllike (ABC) subtypes. PMBL-specific gene expression profiles have been reported, but in clinical practice, the diagnosis of PMBL remains essentially based on clinical, pathological and immunophenotypic characteristics that lack specificity [1, 2] . PMBL is thought to arise from thymic medullary B-cells and to manifest as an anterior mediastinal mass, predominantly in young women [3] .
It is characterized by the constitutive activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway [4] . Recently, RNA-Seq experiments identified somatic coding sequence mutations in PMBL [4] . PMBL mutations led to reduced phosphatase activity of the PTP1B protein, increasing the phosphorylation activity of the JAK-STAT pathway [5] . These mutations likely synergize with other known driver mutations reported in PMBL, including mutations in SOCS1 and STAT6 [4] . Of note, most of these genetic events are commonly shared with classical Hodgkin lymphoma (cHL). In contrast to GCB and ABC DLBCL, EZH2, MYD88 and CD79B mutations or BCL2/BCL6/MYC rearrangements are typically absent from PMBL [6] . We recently detected a recurrent point mutation in the XPO1 (exportin 1) gene (also referred to as chromosome region maintenance 1; CRM1), which results in the Glu571Lys (p.E571K) missense substitution, in refractory / relapsed (R/R) PMBL patients included in the LYSA (Lymphoma Study Association) LNH03 trial program [7, 8] . Exportin-1 (XPO1) is a member of the importin-β superfamily of nuclear export receptors (also termed karyopherins); this superfamily mediates the translocation of numerous RNAs and cellular regulatory proteins, including tumor suppressor proteins (TSPs) such as p53, BRCA1, survivin, NPM, APC, and FOXO. The hydrophobic groove of XPO1 binds to the leucine-rich nuclear export signal (NES) domain of its cargo proteins.
Missense substitutions targeting XPO1 have previously been reported at a low frequency in chronic lymphocytic leukemia (CLL) and esophageal squamous cell carcinoma (ESCC), suggesting that these mutations may play a role in several oncogenic processes [9, 10] . A mutation had also been identified by RNA sequencing in one PMBL case [5] . In addition, cryptic XPO1-MLLT10
translocations have been reported in T-cell acute lymphoblastic leukemia (T-ALL) [11] . Importantly, Selective Inhibitors of Nuclear Export (SINE) compounds, a new class of small molecule inhibitors, have been shown to effectively target XPO1 and retain TSPs in the nucleus. SINE are currently being 4 tested in phase 1 and 2 clinical trials for various cancer types [12, 13] . In this study, we investigated the prevalence, specificity, and biological and clinical relevance of XPO1 mutations in PMBL cases and demonstrated that these mutations represent a new genetic hallmark of the PMBL subtype and cHL based on the rarity or absence of these mutations from GCB/ABC DLBCL or mediastinal gray-zone lymphoma (MGZL) cases. Becquerel Center, Rouen, France); this cohort was referred to as monocentric histologically defined PMBL cohort 1 (hPMBL1). The fourth group, referred to as multicentric histologically defined PMBL cohort 2 (hPMBL2), included other PMBL cases enrolled in multicentric LNH03 LYSA program trials or in the 075 GOELAMS trial (hPMBL2) [14] [15] [16] [17] [18] . These cases were selected by experimented hematopathologists according to typical pathological and clinical criteria (n=47). Written informed consent was obtained from all participants at the time of enrollment for the patients included in the LYSA clinical trials.
Material and Methods

•
• Hodgkin lymphoma samples and microdissection of HRS cells To assess the frequency and specificity of the XPO1 mutations, cases of cHL and MGZL, which are well-known to share several genetic features with PMBL, were analyzed. DNA samples were extracted from micro-dissected Reed-Sternberg (RS) cells of 19 cHL cases (including 7 nodular sclerosis cHL cases, 7 mixed cellularity cHL cases, 3 lymphocyte-rich cHL cases and 2 lymphocytedepleted cHL cases).
HL cells were microdissected from 10-µm-thick sections frozen lymph node sections. RS cells were selected according to CD30 expression and were subsequently microdissected using a PALM • Cell lines
The previously described PMBL-derived cell lines MedB-1, Karpas1106 and U-2940 were kindly provided by Peter Möller (University of Ulm, Germany), Martin Dyer (University of Leicester, United Kingdom) and Christopher Sundström (University of Uppsala, Sweden), respectively [20] [21] [22] . The Jurkat T-ALL cell line was used as a control in some experiments. The cell lines were cultured at 37˚C in a 5% CO 2 • XPO1 sequencing experiments DNA was extracted from frozen or FFPE tumor biopsy samples using standard methods. The patients in mPMBL1 were sequenced using NGS technology (PGM); these results were reported elsewhere (Dubois et al., submitted) . For the other cohorts, standard Sanger sequencing was performed after PCR amplification using the following primers: DNA extracted from frozen tissues: XPO1-ex15F:
GCAATGCATGAAGAGGACG; XPO1-ex15R: TCATTTATTTTGTCCTGGACTCC; DNA extracted from FFPE tissues: XPO1-ex15FFPE-F: TATGTGAACAGAAAAGAGGCAAAG; XPO1-ex15FFPE-R: AAAGAAAGAGATTTACCATGCATG; XPO1-ex15FFPE-F2:
CTCACTGGAAATTTCTGAAGACTGTAG; XPO1-ex15FFPE-R2:
TCATTTATTTTGTCCTGGACTCC. To improve the sensibility of XPO1 mutation detection in cHL and MGZL, we designed a dedicated XPO1 digital PCR (dPCR) assay (for details of the assay, see supplementary file and [23] ).
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• Comparative genomic hybridization (CGH) arrays
To assess the XPO1 copy number, CGH was performed on 208 DLBCL biopsies and a normal commercial DNA pool (Promega, Mannheim, Germany) using 4x180K SurePrint G3 Human CGH microarrays (Agilent, Santa Clara, CA). Primary analysis was performed using Feature Extractor (10.5.1.1); probe-level signals were segmented using the CBS algorithm ("DNAcopy" R package, version 1.36.0); and copy number variations (CNVs) were called using sample-specific log-ratio thresholds accounting for the estimated cellularity of the samples. The resulting copy number data were queried and visualized using Rgb [24] .
• Gene expression profiling (GEP)
Patients were classified into the GCB, ABC, PMBL and "other" (unclassified) subtypes based on published signatures using HGU133 Plus2.0 Affymetrix GeneChip arrays (Affymetrix) (Supplementary Methods). A single probe set was selected to represent the expression of each gene of interest based on JetSet "best" probe set selection (version 2.14.0) [25] . XPO1-based comparative expression analysis was performed using LIMMA to model the expression of 15 262 probe sets according to the XPO1 mutation and binary amplification status [26] . A single probe set was selected to represent the expression of each gene of interest (including XPO1) based on JetSet "best" probe set selection (version 2.14.0) [25] . Only JetSet "best" probe sets displaying a minimal mean expression and variance of 3.5 and 0.05, respectively, were considered for this task.
• Cell proliferation assays
The SINE compound, KPT-185 was provided by Karyopharm Therapeutics (Newton, MA, United • Apoptosis assay
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Cells were harvested after 20 hours of exposure to DMSO or 2 µM KPT-185, washed twice with phosphate-buffered saline, resuspended in Annexin buffer (10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, and 55 mM CaCl2) supplemented with 2.5 µg/ml FITC-labeled Annexin-V (Roche Applied Science, Meylan, France) and incubated at room temperature for 10 minutes. The cells were then washed, resuspended in Annexin buffer supplemented with propidium iodide (3 µg/ml) and analyzed via flow cytometry using a CyAn™ ADP Analyser flow cytometer (Beckman Coulter).
• Transfection of REV-GFP expressing U2OS cells with plasmids encoding XPO1 variants Osteosarcoma U2OS cells, which stably express the fluorescently labelled XPO1 cargo viral protein REV-GFP [27] , were transiently transfected with expression plasmids encoding wild type or E571 mutant XPO1 proteins coupled to a red fluorescent tag. Cells were treated with the clinical SINE compound selinexor (KPT-330, Karyopharm therapeutics) and nuclear localization of REV-GFP and XPO1 was analyzed in transfected cells by confocal microscopy.
• Western blot and immunohistochemistry
Western blot analysis of XPO1 expression was performed according to a standard protocol. First, 10
µg of whole-cell protein extracts were loaded on a precast 4-20% Mini-PROTEAN ® TGX™ Gel • Statistical analysis Tumor responses after induction therapy and at the end of treatment were classified as complete response (CR), unconfirmed complete response (CRu), partial response (PR), stable disease (SD) or progressive disease (PD) based on the International Workshop 1999 Cheson criteria [28] . Progressionfree survival (PFS) was calculated from the date of enrollment to the date of disease progression, relapse, re-treatment or death from any cause. Overall survival was calculated from the date of enrollment or the date of diagnosis to the date of death from any cause. Survival was estimated using the Kaplan-Meier product limit method, and the results were compared using the log-rank test. A Fisher exact-test was used to assess the associations between the XPO1 genotype and patient characteristics.
Results
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• XPO1 mutations are highly specific for the PBML subtype and are located in the NESbinding domain Importantly, the E571K variant was detected as a heterozygous mutation in MedB-1, a PMBL-derived cell line, whereas the two other PMBL cell lines tested, Karpas1106 and U-2940, did not display any variants in XPO1 exon 15.
• XPO1 mutations, CNV and GEP XPO1 is located on chromosome 2p15 near the c-REL 2p16.1 locus; well-known for gains or amplifications in PMBL, GCB-DLBCL and cHL [3, [32] [33] [34] [35] . In the 20 PMBL cases analyzed via CGH, copy number gains in the XPO1 locus were observed in 8 cases (40%, ranging from 3 to 7 copies, Supplementary Figure 1A) ; this rate was higher than that observed for ABC DLBCL (8/70, 11%) but similar to that observed for GCB DLBCL (21/74, 28%). A significant correlation was observed between the XPO1 copy number and the expression of the corresponding mRNA, suggesting a gene 9 dosage effect (p=0.00106, Mann-Whitney test). In contrast, we did not observe any correlation between the XPO1 mutation status and the level of XPO1 mRNA expression (Supplementary Figure   1A) . There was no significant difference in the level of XPO1 mRNA expression between the PMBL, ABC and GCB subtypes (Supplementary Figure 1B) . In all PMBL cases, XPO1 gene copy gains were associated with REL copy gains, and in all but one DLBCL case (Supplementary Figure 1C) .
One case (GHE1287) displayed an XPO1 mutation, 7 copies of the gene and 11 copies of REL.
Overall 13/18 PMBL cases (72%) display either copy gains and/or XPO1 mutations. Of note, MedB-1 and Karpas1106 cells are also known to display 2p16 copy number gains [33] .
We then compared GEPs of mutated and wild-type XPO1 patients using a multivariate model including the amplification status. We observed a significantly higher level of expression of several genes (FDR < 0.1), including PARP15, in PMBL cases harboring XPO1 mutations compared to PMBL cases harboring wild-type XPO1 (Supplementary Figure 1C and supplementary table 2 ).
Interestingly, PARP-15 (also referred to as ARTD7 or BAL3) is a nuclear protein containing Nterminal macro domains and displaying C-terminal poly(ADP-ribose) polymerase (PARP) activity, which was originally reported in refractory/aggressive B-cell lymphoma [36] . • Functional characterization of PMBL cell lines carrying WT or mutant XPO1.
To assess the biological impact of the E571K variant on SINE compound sensitivity, we evaluated the effects of KPT-185, a SINE compound, on PMBL cell lines and compared the results to those described for Jurkat T-ALL cells, which are known to be highly sensitive to this compound [12, 37] . ( Figure 3E ). Taken together, these results show that PMBL cell lines are sensitive to the SINE compound. The MedB-1 cell line, which carries a heterozygous XPO1 E571K mutation, displayed a slightly weaker response to KPT-185 than the Karpas1106 and U-2940 cell lines but remains responsive to this drug, with an EC50 comparable to that for the other PMBL cell lines and on the same order of magnitude as the EC50 for CLL cells [13] .
In keeping with these results, the E571 mutated XPO1 proteins were inhibited by Selinexor in U2OS cells. KPT-330 Treatment inhibited the nuclear export of REV-GFP similarly in cells expressing wildtype and E571 mutated XPO1 protein. By contrast, when XPO1 cysteine 528 was mutated to serine, the ability of selinexor to bind covalently to XPO1 was prevented and therefore nuclear export was not blocked (Figure 3 ).
• Clinical relevance of XPO1 mutations for PMBL Figures 4A and 4C) . In contrast, based on a median follow-up duration of 37 months, we did not observe any prognostic impact of the XPO1 mutation status in the hPMBL cohort (Supplementary Figures 4B and 4D ). mutation [33, 39, 40] . The XPO1 mutation appears to serve as a distinctive genetic feature that facilitates the differential diagnosis of PMBL from DLBCL with mediastinal involvement, or MGZL, which are genetically similar but clearly distinct in their natural history and outcome [41, 42] . Our data enrich the complex genomic landscape and genetic particularity of the PMBL entity, as recently highlighted by a study that used RNAseq and WGS approaches [5] .
In contrast to XPO1 mutations, gains at the chromosome 2p16.1-2p15 locus, which contains both the REL and XPO1 genes, were commonly observed in GCB DLBCL, cHL and PMBL cases [33] [34] [35] .
However, only the putative effect of such gains on c-REL expression and the resulting alterations in the NFKB pathway have been deeply investigated [43] . The frequent genomic overrepresentation of REL in PMBL does not necessarily correlate with NFKB activation, suggesting that the growth advantage related to 2p16.1-15 gains could be related to other candidate genes, such as BCL11A and XPO1 [35] .
Despite similar clinical features between the two cohorts, the rate of XPO1 mutations strongly differed between hPMBL and mPMBL (13% and 64%, respectively). These contrasting results most likely highlight the difficulty in distinguishing "true" PMBL from other subtypes of DLBCL with mediastinal involvement, as initially reported by Rosenwald et al., who established a molecular signature of PMBL [1] . A recent study identified GEP-defined PMBL without any mediastinal involvement, suggesting that GEP definition and genotype are more effective to delineate this entity than anatomical and histopathological criteria [44] . Therefore, XPO1 mutations, in combination with other recurrent reported SNVs and GEP results, contribute to the more accurate elucidation of the molecular basis of this lymphoma subtype.
The functional relevance of the E571K variant is currently unknown. Preliminary structural analysis suggests that E571 mutations likely affect cargo NES binding and may change the open-closed 12 equilibrium of the hydrophobic groove of XPO1. For instance, the E571-K568 salt bridge, which has been observed in every XPO1 structure, sits at the narrowest part of the NES groove and is likely important for groove shape (unpublished data courtesy of Dr. Chook, University of Texas). Most of the reported genetic alterations in PMBL, including JAK2 gains and STAT6, SOCS1 or PTPN1 mutations, coincide and synergize to activate the JAK-STAT6 pathway [39, 45] . XPO1 is known to be involved in the nucleo-cytoplasmic export of STAT1, which is also known to be highly expressed in PMBL; therefore, XPO1 may contribute to the tuning of the JAK-STAT pathway [2, 46] . Other proteins known to play an important role in PMBL pathophysiology, including CIITA, IKBKB and FOXO1, are also under the control of XPO1 cargo function [47] [48] [49] [50] . Importantly, E571 is located in a highly charged region of the NES groove, which surrounds cysteine residue 528 (C528), known to be the conjugation site of KPT-185/KPT-330/LMB [53] . Therefore, mutations in E571 may also affect the rates of conjugation and deconjugation of these molecules.
However, our results indicate that the inhibition of XPO1 by KPT-185 / KPT-330 is cytotoxic to all PMBL cell lines and effective in XPO1 mutant transfected U2OS cells, suggesting no major impact of the E571 variant in SINE compounds efficacy.
The differential GEP observed between the XPO1 mutant and WT PMBL cases, including a higher expression level of PARP15/BAL3 and several genes controlled by TCF3, strongly suggests a functional impact of XPO1 mutations 46 .
Increased XPO1 expression has been associated with poor prognosis in MCL and ovarian cancer patients and has been detected in several other cancers such as glioma, osteosarcoma, and pancreatic and cervical cancer [54, 55] . In CLL, the prognostic value of XPO1 mutations is unclear [9] . Based on our study, the prognostic impact of XPO1 mutations on PMBL is also uncertain. In the mPMBL cohort, XPO1 mutations were highly prevalent (50%) and were observed in unusual relapsing or refractory cases; these results contrasted with the absence of an impact of these mutations on the hPMBL cohort. The more frequent rituximab usage in hPMBL patients (76/85, 89%) than in mPMBL patients (15/32, 47%), as well as a fivefold lower mutation rate in hPMBL than in mPMBL, may 13 explain these inconclusive results regarding the prognostic impact of XPO1 mutations. Furthermore, the proportion of patients who received adjuvant radiotherapy was different between mutated (3.5%) and unmutated patients (9%) and may have played a role in reducing the number of progressions in this group. However, one could hypothesize that in rare PMBL cases, XPO1 mutations may synergize with additional genetic events to favor chemotherapy resistance.
In conclusion, although the oncogenic properties of XPO1 mutations remain to be determined, their recurrent selection in PMBL and cHL strongly supports their involvement in the pathogenesis of these diseases.
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